ArriVent BioPharma (AVBP) Operating Leases (2023 - 2026)

ArriVent BioPharma has disclosed Operating Leases across 3 years of filings, most recently posting $320000.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $320000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $320000.0 (changed N/A YoY), and the FY2024 annual result was $14000.0, down 92.09% from the prior year.
• Operating Leases came in at $320000.0 for Q1 2026 at ArriVent BioPharma, up from $14000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $320000.0 in Q1 2026 to a low of $14000.0 in Q4 2024.
• The 3-year median for Operating Leases is $118000.0 (2024), against an average of $133833.3.
• Peak annual rise in Operating Leases reached 92.09% in 2024, while the deepest fall reached 92.09% in 2024.
• ArriVent BioPharma's Operating Leases stood at $177000.0 in 2023, then plunged by 92.09% to $14000.0 in 2024, then surged by 2185.71% to $320000.0 in 2026.
• The last three Operating Leases figures came in at $320000.0 (Q1 2026), $14000.0 (Q4 2024), and $56000.0 (Q3 2024), per Business Quant data.